• 8:30 - 18:00 M-T / 8.30 - 15.00 F

Reoxcare continues its growth in the wound care market with the participation in the 8th International Symposium on the Diabetic Foot


From the 22nd to the 25th of May, the 8th International Symposium on the Diabetic Foot was held in The Hague – The Netherlands, and Histocell took part in this event, participating as an exhibitor and presenting a scientific poster.

The International Symposium on the Diabetic Foot is organised every four years and is the largest and most prestigious meeting devoted to lower extremity problems in diabetes. It has accomplished this unique position by bringing together delegates from many specialties and the leading experts in various fields, both from all over the world.

Given the importance of this congress, and following Histocell’s strategy to publicise both the commercial and scientific aspects of an innovative product such as Reoxcare, it was decided to be present with a booth and presenting a scientific poster, which could offer more specific data to the experts attending.

The poster, presented with the title “Adequate management of oxidative stress in wound environment, significantly improves the healing of neuroischemic postsurgical diabetic foot ulcers”, informs of the options for a common situation in the field.

Many people visited our Reoxcare stand, well-known industry leaders, users, and more than 100 visitors who had the opportunity to get to know the benefits of the use of the wound dressing, marketed in Spain in 2018. Reoxcare is also available internationally in Colombia, Chile, Peru and Mexico in America, as well as Italy in Europe, with a short-term expansion plan for Jordan, Saudi Arabia, Ecuador, Panama, Austria, Serbia, The Netherlands, Greece and Cyprus.

About Reoxcare

Reoxcare® is an antioxidant wound dressing with ingredients from natural origin, unique within the range of products so far used for the treatment of chronic wounds. With more than 30 preclinical and clinical studies carried out, Reoxcare® has demonstrated unique antioxidant properties and the ability to induce a natural healing in highly inflammatory environments, the main cause of chronification of wounds such as vascular origin ulcers or pressure ulcers, and has demonstrated to be particularly effective in diabetic foot ulcers.

Chronic wounds are a serious health and economic problem worldwide. It is estimated that there are about 175 million new cases every year, including pressure ulcers, vascular or diabetic. 28 million people suffer from chronic wounds annually and the estimated market this year for the treatment of these injuries is more than 5,000 million euros.

Histocell Headquarters

Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900

Histocell Factory

Polígono Sasine. Patakon s/n
48195 Larrabetzu
Bizkaia - Spain

+34 94 656 7900

Our mision

We develop new advanced therapy medicinal products, medical devices and dermocosmetics to improve people's quality of life.

Copyright © Histocell